Reporting owner · CIK 0001796226

Murphy Andrew J

SEC Form 4 history across 1 companies, 30 transactions and 1 filings.

CSOCo-Chief Scientific OfficerREGENERON PHARMACEUTICALS, INC.
Open-market transaction mix0% buys0 buys · 27 sales
Latest filingOct 15, 2026, 08:02 PM

Available history · Oct 13, 2026 – Oct 14, 2026

Filings1Form 4 records
Buying$00 purchases
Selling$3.2M27 sales
Net value−$3.2MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from available history.
Murphy Andrew J transactions · 20 per page
CompanyInsiderActivityDisclosed valueFiled (ET)
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$41.9kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$20.5kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$56.2kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$10.6kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$18.1kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$12.1kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$26.4kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOS · sale10b5-1 detectedSEC filing ↗-$4.52kView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOF · withholding10b5-1 detectedSEC filing ↗-$9.69MView disclosure →
REGNREGENERON PHARMACEUTICALS, INC.
Murphy Andrew JCSOM · exercise10b5-1 detectedSEC filing ↗$6.49MView disclosure →
Open a transaction for shares, transaction date, ownership and the original SEC filing.

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

sale at REGENERON PHARMACEUTICALS, INC. on Oct 14, 2026 valued at $39,074.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at REGENERON PHARMACEUTICALS, INC. on Oct 14, 2026 valued at $39,074.

Review SEC filing

Monthly open-market activity

Last 1 reported months · purchases and sales

View exact monthly values
MonthPurchasesSalesBuy valueSale valueNet value
Oct 2026027$0.00$3,204,375.76-$3,204,375.76

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$118.7K
Median P/S size$80.7K
Direct30
Indirect0
Oct 14, 2026sale

Filing-only signals

Deterministic matches in this insider's history

Derivative Transactionfiling-context1Direct Ownershipfiling-context30Large Holdings Increaseholdings1Large Holdings Reductionholdings1Large Salesize15Repeat Sellerpattern2210b5-1 Detectedfiling-context30

Associated companies

Companies in the disclosed reporting history

REGENERON PHARMACEUTICALS, INC.REGN · 30 transactions · latest Oct 15, 2026, 08:02 PM

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in available history

A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

29 observations · Oct 13, 2026 – Oct 14, 2026. Window ends at the latest available report, not today.

Selected observation · Oct 14, 202647,833 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Oct 13, 202664,833Oct 15, 2026View transaction
Oct 13, 202651,980Oct 15, 2026View transaction
Oct 14, 202651,974Oct 15, 2026View transaction
Oct 14, 202651,939Oct 15, 2026View transaction
Oct 14, 202651,923Oct 15, 2026View transaction
Oct 14, 202651,899Oct 15, 2026View transaction
Oct 14, 202651,885Oct 15, 2026View transaction
Oct 14, 202651,811Oct 15, 2026View transaction
Oct 14, 202651,784Oct 15, 2026View transaction
Oct 14, 202651,729Oct 15, 2026View transaction
Oct 14, 202651,704Oct 15, 2026View transaction
Oct 14, 202651,485Oct 15, 2026View transaction
Oct 14, 202651,214Oct 15, 2026View transaction
Oct 14, 202650,935Oct 15, 2026View transaction
Oct 14, 202650,743Oct 15, 2026View transaction
Oct 14, 202650,638Oct 15, 2026View transaction
Oct 14, 202650,511Oct 15, 2026View transaction
Oct 14, 202650,499Oct 15, 2026View transaction
Oct 14, 202650,216Oct 15, 2026View transaction
Oct 14, 202650,005Oct 15, 2026View transaction
Oct 14, 202649,781Oct 15, 2026View transaction
Oct 14, 202649,660Oct 15, 2026View transaction
Oct 14, 202649,284Oct 15, 2026View transaction
Oct 14, 202649,218Oct 15, 2026View transaction
Oct 14, 202649,180Oct 15, 2026View transaction
Oct 14, 202648,726Oct 15, 2026View transaction
Oct 14, 202648,346Oct 15, 2026View transaction
Oct 14, 202647,883Oct 15, 2026View transaction
Oct 14, 202647,833Oct 15, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Murphy Andrew J Insider Activity FAQ

SEC Form 4 context

Who is Murphy Andrew J?

Murphy Andrew J is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001796226.

Which companies has Murphy Andrew J reported transactions for?

REGENERON PHARMACEUTICALS, INC.

When was Murphy Andrew J's latest insider buy?

No open-market insider purchase is available for this period.

When was Murphy Andrew J's latest insider sale?

sale at REGENERON PHARMACEUTICALS, INC. on Oct 14, 2026 valued at $39,074.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.